Tanios Bekaii-Saab, MD

Articles

Dr. Bekaii-Saab Discusses the Next Steps With Regorafenib in CRC

April 3rd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the next steps following for regorafenib (Stivarga) in colorectal cancer (CRC).

Dr. Bekaii-Saab Discusses PEGPH20 in Pancreatic Adenocarcinoma

March 2nd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses pegylated recombinant human hyaluronidase (PEGPH20) in pancreatic adenocarcinoma.

Dr. Bekaii-Saab on the Impact of Regorafenib in CRC

February 23rd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the impact of regorafenib (Stivarga) on the treatment of patients with colorectal cancer (CRC).

Dr. Bekaii-Saab on the Importance of the ReDOS Study in mCRC

February 14th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the importance of the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer (mCRC).

Dr. Bekaii-Saab Discusses the ReDOS Study in Metastatic CRC

February 6th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer.

Dr. Bekaii-Saab Discusses QoL With Regorafenib Dose Escalation in mCRC

January 23rd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the quality of life findings for a dose-escalation study of regorafenib (Stivarga) in metastatic colorectal cancer.

Dr. Bekaii-Saab on the Response Rate of Pembrolizumab in MSI-H CRC

November 1st 2017

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the response rate of pembrolizumab (Keytruda) for patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC).

Dr. Saab on Immunotherapy in MSI-H GI Malignancies

September 23rd 2017

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses immunotherapy in a patient with microsatellite instability-high (MSI-H) gastrointestinal malignancies.

Dr. Bekaii-Saab on the Potential Impact of Napabucasin Combo in Pancreatic Cancer

July 13th 2017

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the potential impact of the combination of napabucasin with gemcitabine and nab-paclitaxel in pancreatic cancer.

Dr. Saab on Napabucasin With Gemcitabine and Nab-Paclitaxel in Pancreatic Adenocarcinoma

June 30th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses napabucasin with gemcitabine and nab-paclitaxel in pancreatic adenocarcinoma.

Dr. Saab on Napabucasin (BBI-608) in Colorectal Cancer Treatment

June 20th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the stemness inhibitor napabucasin (BBI-608) as a potential treatment for patients with colorectal cancer (CRC).

Dr. Bekaii-Saab on Napabucasin Plus Nab-paclitaxel/Gemcitabine in Pancreatic Cancer

June 16th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses a phase I study of napabucasin plus nab-paclitaxel (Abraxane) and gemcitabine for the treatment of patients with pancreatic cancer.

Dr. Bekaii-Saab on Results of the IDEA Project for Colon Cancer

June 9th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the results of the phase III IDEA project for patients with stage III colon cancer.

Dr. Bekaii-Saab on Expanding Landscape in CRC

March 1st 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the expanding treatment landscape of colorectal cancer (CRC).

Dr. Bekaii Saab on Immunotherapeutic Options in CRC Beyond PD-1/PD-L1

January 12th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses immunotherapeutic options being explored in the treatment landscape of colorectal cancer (CRC) beyond PD-1/PD-L1 agents.

Dr. Bekaii-Saab on the Role of Immunotherapy in CRC

December 23rd 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the role of immunotherapy in the treatment of patients with colorectal cancer.

Dr. Bekaii-Saab on the Expansion of Treatment Options in Colorectal Cancer

December 16th 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the recent expansion of treatment options available for patients with colorectal cancer.

Dr. Tanios Bekaii-Saab on Sequencing Questions in mCRC

November 29th 2016

Tanios Bekaii-Saab, MD, a professor of Medicine at Mayo Clinic, discusses sequencing regorafenib (Stivarga) and TAS-102 (Lonsurf) in metastatic colorectal cancer (mCRC).

Dr. Bekaii-Saab Compares Toxicities of Regorafenib and TAS-102 in Colorectal Cancer

November 22nd 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, compares the toxicity profiles of regorafenib and TAS-102, which are both used to treat patients with metastatic colorectal cancer.

Dr. Bekaii-Saab on Differences Between Regorafenib and TAS-102 in CRC

September 20th 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses regorafenib and TAS-102. In colorectal cancer.